Dabigatran ( DrugBank: Dabigatran )

---

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
85	特発性間質性肺炎	1
91	バッド・キアリ症候群	1
124	皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症	1

51. 全身性強皮症

---

臨床試験数 : 523 /  薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02426229 (ClinicalTrials.gov)	February 2016	4/3/2015	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Scleroderma;Interstitial Lung Disease	Drug: dabigatran etexilate	Medical University of South Carolina	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	70 Years	All	15	Phase 1	United States

85. 特発性間質性肺炎

---

臨床試験数 : 598 /  薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02885961 (ClinicalTrials.gov)	August 2016	15/8/2016	The Coagulation Cascade in Idiopathic Pulmonary Fibrosis	Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis;IPF;Interstitial Lung Disease	Drug: Dabigatran;Radiation: FDG PET scan	University College, London	NULL	Not yet recruiting	40 Years	80 Years	Both	12	N/A	NULL

91. バッド・キアリ症候群

---

臨床試験数 : 4 /  薬物数 : 5 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000015319	2012/06/01	12/10/2014	The efficacy of dabigatran for portal vein thrombosis/Budd-Chiari syndrome		Portal vein thrombosis or Budd-Chiari syndrome	dabigatran	Chiba University Graduate School of Medicine, Department of Gastroenterology and Nephrology	NULL	Recruiting	20years-old	70years-old	Male and Female	20	Not selected	Japan

124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症

---

臨床試験数 : 12 /  薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01361763 (ClinicalTrials.gov)	June 2011	16/5/2011	Safety Study of Dabigatran in CADASIL	Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL	CADASIL	Drug: Dabigatran;Drug: Antiplatelets	S. Andrea Hospital	NULL	Recruiting	18 Years	N/A	Both	50	Phase 2	Italy